Juan Carlos Montejo González
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Juan Carlos Montejo González has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Annika Reintam Blaser
Department of Anaesthesiology and Intensive Care University of Tartu Tartu Estonia
5 shared publications - Arthur Raymond Hubert van Zanten
Department of Intensive Care Medicine & Research, Gelderse Vallei Hospital, Ede
5 shared publications - Jean-Charles Preiser
Internal Medicine Department, Institut Jules Bordet—Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium
4 shared publications - Mette M. Berger
Faculty of Biology & Medicine, Lausanne University, Lausanne, Switzerland
4 shared publications - Michael Paul Casaer
Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
4 shared publications - Pierre Singer
Intensive Care Unit, School of Medicine, Herzlia Medical Center, Reichman University, Herzlia, Israel
4 shared publications
Latest Publications
- Open Access
- 1 January 2024
- Published by ARAN Ediciones in Nutrición Hospitalaria
- Vol. 41, 19-21
A shared experience between services
Revista oficial de la Sociedad Española de Nutrición Parenteral y de la Sociedad Española de Nutrición. Está dedicada al estudio y divulgación de temas relacionados con la nutrición.
- 1 January 2024
- Published by ARAN Ediciones in Nutrición Hospitalaria
- Vol. 41, 19-21
Open AccessA shared experience between services
Revista oficial de la Sociedad Española de Nutrición Parenteral y de la Sociedad Española de Nutrición. Está dedicada al estudio y divulgación de temas relacionados con la nutrición.
- Top Cited Papers
- 14 July 2023
- Published by Elsevier in Clinical Nutrition
- Vol. 42 (9) , 1671-1689
ESPEN practical and partially revised guideline: Clinical nutrition in the intensive care unit
- 14 July 2023
- Published by Elsevier in Clinical Nutrition
- Vol. 42 (9) , 1671-1689
Top Cited PapersESPEN practical and partially revised guideline: Clinical nutrition in the intensive care unit
- 26 December 2022
- Published by Elsevier in Clinical Nutrition
- Vol. 42 (3) , 440-441
Erratum to “TICACOS international: A multi-center, randomized, prospective controlled study comparing tight calorie control versus liberal calorie administration study” (1)
- 26 December 2022
- Published by Elsevier in Clinical Nutrition
- Vol. 42 (3) , 440-441
Erratum to “TICACOS international: A multi-center, randomized, prospective controlled study comparing tight calorie control versus liberal calorie administration study” (1)
- Open Access
- 8 September 2022
- Published by Sociedad Ecuatoriana de Nefrologia, Dialisis y Trasplantes in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
- Vol. 10 (2) , 97-107
Obesidad y enfermedad renal crónica. Una mirada desde los mecanismos fisiopatológicos.
Introduction: Chronic kidney disease associated with obesity (CKD-WO) has increased in prevalence in recent decades. It is characterized by excess adipocytic hormonal imbalances (adipokines), deregulation of the energy balance system, and imbalances in metabolic homeostasis. Purpose of the review: The objective is to outline the different pathophysiological mechanisms' role in developing functional or anatomical kidney disease in obese patients. We look for updated reports that include the best survival results for patients with CKD. Recent findings: We currently know that CKD-WO has a chronic pro-inflammatory behavior. Obesity and overweight are associated with hemodynamic, structural, and histopathological alterations in the kidney and metabolic and biochemical alterations that predispose to kidney disease, even when renal function and conventional tests are normal. Conclusions: We classify CKD-WO in Type 1: Obesity and potentially reversible functional alterations. Type 2: Obesity and potentially non-reversible histopathological structural alterations (includes glomerulopathy associated with obesity and focal segmental glomerulosclerosis). Type 3: Obesity-related to chronic diseases (diabetes, hypertension, pulmonary hypertension, heart failure). Type 4: Obesity in the patient with renal function replacement therapy.
- 8 September 2022
- Published by Sociedad Ecuatoriana de Nefrologia, Dialisis y Trasplantes in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
- Vol. 10 (2) , 97-107
Open AccessObesidad y enfermedad renal crónica. Una mirada desde los mecanismos fisiopatológicos.
Introduction: Chronic kidney disease associated with obesity (CKD-WO) has increased in prevalence in recent decades. It is characterized by excess adipocytic hormonal imbalances (adipokines), deregulation of the energy balance system, and imbalances in metabolic homeostasis. Purpose of the review: The objective is to outline the different pathophysiological mechanisms' role in developing functional or anatomical kidney disease in obese patients. We look for updated reports that include the best survival results for patients with CKD. Recent findings: We currently know that CKD-WO has a chronic pro-inflammatory behavior. Obesity and overweight are associated with hemodynamic, structural, and histopathological alterations in the kidney and metabolic and biochemical alterations that predispose to kidney disease, even when renal function and conventional tests are normal. Conclusions: We classify CKD-WO in Type 1: Obesity and potentially reversible functional alterations. Type 2: Obesity and potentially non-reversible histopathological structural alterations (includes glomerulopathy associated with obesity and focal segmental glomerulosclerosis). Type 3: Obesity-related to chronic diseases (diabetes, hypertension, pulmonary hypertension, heart failure). Type 4: Obesity in the patient with renal function replacement therapy.
- 13 April 2022
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 46 (6) , 1420-1430
Enteral nutrition in critically ill patients under vasoactive drug therapy: The NUTRIVAD study
Background: Enteral nutrition (EN) in critically ill patients requiring vasoactive drug (VAD) support is controversial. This study assesses the tolerability and safety of EN in such patients.Methods: This prospective observational study was conducted in 23 intensive care units (ICUs) over 30 months. Inclusion criteria were a need for VADs and/or mechanic circulatory support (MCS) over a minimum of 48 h, a need for ≥48 h of mechanical ventilation, an estimated life expectancy >72 h, and ≥72 h of ICU stay. Patients with refractory shock were excluded. EN was performed according to established protocols during which descriptive, daily hemodynamic and efficacy, and safety data were collected. An independent research group conducted the statistical analysis.Results: Of 200 patients included, 30 (15%) required MCS and 145 (73%) met early multiorgan dysfunction criteria. Mortality was 24%. Patients needed a mean dose of norepinephrine in the first 48 h of 0.71 mcg/kg/min (95% CI, 0.63–0.8) targeting a mean arterial pressure of 68 mm Hg (95% CI, 67–70) during the first 48 h. EN was started 34 h (95% CI, 31–37) after ICU admission. Mean energy and protein delivered by EN/patient/day were 1159 kcal (95% CI, 1098–1220) and 55.6 g (95% CI, 52.4–58.7), respectively. Daily energy balance during EN/patient/day was −432 (95% CI, −496 to −368). One hundred and fifty‐four (77%) patients experienced EN‐related complications. However, severe complications, such as mesenteric ischemia, were recorded in only one (0.5%) patient.Conclusion: EN in these patients seems feasible, safe, and unrelated to serious complications. Reaching the energy target only through EN is difficult.
- 13 April 2022
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 46 (6) , 1420-1430
Enteral nutrition in critically ill patients under vasoactive drug therapy: The NUTRIVAD study
Background: Enteral nutrition (EN) in critically ill patients requiring vasoactive drug (VAD) support is controversial. This study assesses the tolerability and safety of EN in such patients.Methods: This prospective observational study was conducted in 23 intensive care units (ICUs) over 30 months. Inclusion criteria were a need for VADs and/or mechanic circulatory support (MCS) over a minimum of 48 h, a need for ≥48 h of mechanical ventilation, an estimated life expectancy >72 h, and ≥72 h of ICU stay. Patients with refractory shock were excluded. EN was performed according to established protocols during which descriptive, daily hemodynamic and efficacy, and safety data were collected. An independent research group conducted the statistical analysis.Results: Of 200 patients included, 30 (15%) required MCS and 145 (73%) met early multiorgan dysfunction criteria. Mortality was 24%. Patients needed a mean dose of norepinephrine in the first 48 h of 0.71 mcg/kg/min (95% CI, 0.63–0.8) targeting a mean arterial pressure of 68 mm Hg (95% CI, 67–70) during the first 48 h. EN was started 34 h (95% CI, 31–37) after ICU admission. Mean energy and protein delivered by EN/patient/day were 1159 kcal (95% CI, 1098–1220) and 55.6 g (95% CI, 52.4–58.7), respectively. Daily energy balance during EN/patient/day was −432 (95% CI, −496 to −368). One hundred and fifty‐four (77%) patients experienced EN‐related complications. However, severe complications, such as mesenteric ischemia, were recorded in only one (0.5%) patient.Conclusion: EN in these patients seems feasible, safe, and unrelated to serious complications. Reaching the energy target only through EN is difficult.
- Open Access
- 7 January 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-10
Study of risk factors for healthcare-associated infections in acute cardiac patients using categorical principal component analysis (CATPCA)
Using categorical principal component analysis, we aimed to determine the relationship between health care-associated infections (HAIs) and diagnostic categories (DCs) in patients with acute heart disease using data collected in the Spanish prospective ENVIN-HELICS intensive care registry over a 10-year period (2005–2015). A total of 69,876 admissions were included, of which 5597 developed HAIs. Two 2-component CATPCA models were developed. In the first model, all cases were included; the first component was determined by the duration of the invasive devices, the ICU stay, the APACHE II score and the HAIs; the second component was determined by the type of admission (medical or surgical) and by the DCs. No clear association between DCs and HAIs was found. Cronbach’s alpha was 0.899, and the variance accounted for (VAF) was 52.5%. The second model included only admissions that developed HAIs; the first component was determined by the duration of the invasive devices and the ICU stay; the second component was determined by the inflammatory response, the mortality in the ICU and the HAIs. Cronbach’s alpha value was 0.855, and VAF was 46.9%. These findings highlight the role of exposure to invasive devices in the development of HAIS in patients with acute heart disease.
- 7 January 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-10
Open AccessStudy of risk factors for healthcare-associated infections in acute cardiac patients using categorical principal component analysis (CATPCA)
Using categorical principal component analysis, we aimed to determine the relationship between health care-associated infections (HAIs) and diagnostic categories (DCs) in patients with acute heart disease using data collected in the Spanish prospective ENVIN-HELICS intensive care registry over a 10-year period (2005–2015). A total of 69,876 admissions were included, of which 5597 developed HAIs. Two 2-component CATPCA models were developed. In the first model, all cases were included; the first component was determined by the duration of the invasive devices, the ICU stay, the APACHE II score and the HAIs; the second component was determined by the type of admission (medical or surgical) and by the DCs. No clear association between DCs and HAIs was found. Cronbach’s alpha was 0.899, and the variance accounted for (VAF) was 52.5%. The second model included only admissions that developed HAIs; the first component was determined by the duration of the invasive devices and the ICU stay; the second component was determined by the inflammatory response, the mortality in the ICU and the HAIs. Cronbach’s alpha value was 0.855, and VAF was 46.9%. These findings highlight the role of exposure to invasive devices in the development of HAIS in patients with acute heart disease.
- Top Cited PapersOpen Access
- 14 December 2021
- Published by Springer Nature in Critical Care
- Vol. 25 (1) , 1-13
A guide to enteral nutrition in intensive care units: 10 expert tips for the daily practice
The preferential use of the oral/enteral route in critically ill patients over gut rest is uniformly recommended and applied. This article provides practical guidance on enteral nutrition in compliance with recent American and European guidelines. Low-dose enteral nutrition can be safely started within 48 h after admission, even during treatment with small or moderate doses of vasopressor agents. A percutaneous access should be used when enteral nutrition is anticipated for ≥ 4 weeks. Energy delivery should not be calculated to match energy expenditure before day 4–7, and the use of energy-dense formulas can be restricted to cases of inability to tolerate full-volume isocaloric enteral nutrition or to patients who require fluid restriction. Low-dose protein (max 0.8 g/kg/day) can be provided during the early phase of critical illness, while a protein target of > 1.2 g/kg/day could be considered during the rehabilitation phase. The occurrence of refeeding syndrome should be assessed by daily measurement of plasma phosphate, and a phosphate drop of 30% should be managed by reduction of enteral feeding rate and high-dose thiamine. Vomiting and increased gastric residual volume may indicate gastric intolerance, while sudden abdominal pain, distension, gastrointestinal paralysis, or rising abdominal pressure may indicate lower gastrointestinal intolerance.
- 14 December 2021
- Published by Springer Nature in Critical Care
- Vol. 25 (1) , 1-13
Top Cited PapersOpen AccessA guide to enteral nutrition in intensive care units: 10 expert tips for the daily practice
The preferential use of the oral/enteral route in critically ill patients over gut rest is uniformly recommended and applied. This article provides practical guidance on enteral nutrition in compliance with recent American and European guidelines. Low-dose enteral nutrition can be safely started within 48 h after admission, even during treatment with small or moderate doses of vasopressor agents. A percutaneous access should be used when enteral nutrition is anticipated for ≥ 4 weeks. Energy delivery should not be calculated to match energy expenditure before day 4–7, and the use of energy-dense formulas can be restricted to cases of inability to tolerate full-volume isocaloric enteral nutrition or to patients who require fluid restriction. Low-dose protein (max 0.8 g/kg/day) can be provided during the early phase of critical illness, while a protein target of > 1.2 g/kg/day could be considered during the rehabilitation phase. The occurrence of refeeding syndrome should be assessed by daily measurement of plasma phosphate, and a phosphate drop of 30% should be managed by reduction of enteral feeding rate and high-dose thiamine. Vomiting and increased gastric residual volume may indicate gastric intolerance, while sudden abdominal pain, distension, gastrointestinal paralysis, or rising abdominal pressure may indicate lower gastrointestinal intolerance.
- Open Access
- 1 February 2021
- Published by Elsevier in Clinical Nutrition
- Vol. 40 (2) , 590-599
Monitoring and parenteral administration of micronutrients, phosphate and magnesium in critically ill patients: The VITA-TRACE survey
- 1 February 2021
- Published by Elsevier in Clinical Nutrition
- Vol. 40 (2) , 590-599
Open AccessMonitoring and parenteral administration of micronutrients, phosphate and magnesium in critically ill patients: The VITA-TRACE survey
- 1 February 2021
- Published by Elsevier in Clinical Nutrition
- Vol. 40 (2) , 380-387
TICACOS international: A multi-center, randomized, prospective controlled study comparing tight calorie control versus Liberal calorie administration study
- 1 February 2021
- Published by Elsevier in Clinical Nutrition
- Vol. 40 (2) , 380-387
TICACOS international: A multi-center, randomized, prospective controlled study comparing tight calorie control versus Liberal calorie administration study